Capmatinib Diydrochloride Monohydrate and its Impurities

Capmatinib Diydrochloride Monohydrate is brand name Tabrecta. It is an oral targeted therapy drug classified as a MET inhibitor. It is developed by Novartis and approved for use in certain types of lung cancer. Reference standards of Capmatinib Diydrochloride Monohydrate API, and its pharmacopeial, non pharmacopeial impurities, and stable isotopes are listed below.